Results 11 to 20 of about 204,259 (398)

Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30‐day results

Catheterization and Cardiovascular Interventions, Volume 100, Issue 7, Page 1291-1299, December 1, 2022., 2022
Abstract Background Severe tricuspid regurgitation (TR) is independently associated with increased morbidity and mortality. Percutaneous transcatheter approaches may offer an alternative for patients not amenable to surgery. Methods TriCLASP is a prospective, single‐arm, multicenter European post‐market clinical follow‐up study (NCT04614402) to ...
Stephan Baldus, Niklas Schofer, Jörg Hausleiter, Kai Friedrichs, P. Lurz, Philipp Luedike, Christian Frerker, G. Nickenig, Edith Lubos, Roman Pfister, M. I. Körber, Daniel Kalbacher, Michael Näbauer, C. Besler, Amir Abbas Mahabadi, Marcel Weber, M. Zdanyte, C. B. Ren, Tobias Geisler   +18 more
wiley   +1 more source

Long‐term outcome prediction for chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy

Clinical Cardiology, Volume 45, Issue 12, Page 1255-1263, December 2022., 2022
Abstract Background The definitive treatment for chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary endarterectomy (PEA), which has good long‐term outcomes. However, after surgery, a quarter of the patients still have residual pulmonary hypertension (RPH). In pulmonary hemodynamics, there are no unified criteria for RPH, even though the
Wu Song, Jiade Zhu, ZhaoJi Zhong, Yunhu Song, Sheng Liu   +4 more
wiley   +1 more source

Clinical Relevance of Drug–Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Population‐Based Case‐Control Studies in Patients Aged 65–100 Years Using Linked English Primary Care and Hospital Data

Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 423-434, February 2023., 2023
This study evaluated drug–drug interactions (DDIs) between antibiotic and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary based on adverse drug reaction (ADR) detectable with routine International Classification of Diseases, Tenth Revision coding.
Tjeerd Pieter van Staa, Munir Pirmohamed, Anita Sharma, Iain Buchan, Darren M. Ashcroft   +4 more
wiley   +1 more source

Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. [PDF]

PLoS ONE, 2013
Despite the proven efficacy of warfarin, its use in patients with Atrial Fibrillation (AF) is reportedly low. We investigated the underuse and overuse of warfarin in the management of AF in general practices in the United Kingdom (UK) against the ...
Mohammed A Mohammed, Tom Marshall, Krishnarajah Nirantharakumar, Andrew Stevens, David Fitzmaurice   +4 more
doaj   +1 more source

Dabigatran versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2009
BACKGROUND Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin   +19 more
semanticscholar   +1 more source

Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.

JAMA cardiology, 2020
Importance Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of ...
A. Robinson, C. Trankle, G. Eubanks, C. Schumann, P. Thompson, Ryan Wallace, S. Gottiparthi, Benjamin K Ruth, C. Kramer, M. Salerno, K. Bilchick, C. Deen, M. Kontos, J. Dent   +13 more
semanticscholar   +1 more source

Use of warfarin in long-term care: a systematic review

BMC Geriatrics, 2012
Background The use of warfarin in older patients requires special consideration because of concerns with comorbidities, interacting medications, and the risk of bleeding.
Neidecker Marjorie, Patel Aarti A, Nelson Winnie W, Reardon Gregory   +3 more
doaj   +1 more source

Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy [PDF]

, 2017
Warfarin and antihyperlipidemics are commonly co-prescribed. Some antihyperlipidemics may inhibit warfarin deactivation via the hepatic cytochrome P450 system.
Bilker, Warren B., Brensinger, Colleen M., Hennessy, Sean, Kimmel, Stephen E., Leonard, Charles E., Whitaker, Heather J.   +5 more
core   +2 more sources

Edoxaban versus warfarin in patients with atrial fibrillation.

New England Journal of Medicine, 2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.
R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott, J. Halperin, A. Waldo, M. Ezekowitz, J. Weitz, J. Špinar, W. Rużyłło, M. Ruda, Y. Koretsune, Joshua Betcher, M. Shi, L. Grip, Shirali P Patel, Indravadan Patel, J. Hanyok, M. Mercuri, E. Antman   +20 more
semanticscholar   +1 more source

Mekanik Kalp Kapaklı Hastalarda Antikoagülan Kullanımı ve Warfarin Direnci

Ankara Medical Journal, 2015
Amaç: Mekanik kalp kapağı olan hastalarda warfarin direnci olanlar  tespit edildi ve bu hastalarda uygulanan tedavi seçenekleri değerlendirildi.Materyal ve Metot: Çalışmaya 2006-2014 yılları arasında ınr takipleri yapılan mekanik kalp kapağı takılmış 40 ...
Ergun Salman, Kemal Erdoğan, Muhammet Fethi Sağlam, Mete Hıdıroğlu   +3 more
doaj   +1 more source